Prelude Therapeutics is a privately held, clinical-stage precision oncology company based in Wilmington, DE. The company focuses on discovering and developing small-molecule therapies optimized to target key driver mechanisms in cancers with high unmet need. Its lead product candidates are PRMT5 inhibitors PRT543 and PRT811, and PRT1419, a potent and selective inhibitor of the anti-apoptotic protein MCL1. PRT543 is being evaluated in a Phase 1 trial with an initial focus on select solid tumors and myeloid malignancies; PRT811 is in a Phase 1 clinical trial in solid tumors, including glioblastoma multiforme. Prelude is initiating clinical trial activities for PRT1419 in selected hematological malignancies. The company recently closed a $50 million Series C to support growth and advancement of its pipeline and has added two experienced industry executives to its board to support development and corporate efforts. Prelude Therapeutics is a privately held clinical-stage biopharmaceutical company focused on discovering and developing small-molecule drugs that target molecular mechanisms driving cancer growth, survival and resistance. Its lead program is a proprietary PRMT5 inhibitor, PRT543, which is in a parallel dose-escalation Phase 1 clinical trial for solid tumors, myeloid malignancies and lymphomas. PRMT5 is implicated in cancer cell proliferation, cell cycle progression and resistance to apoptosis, and Prelude is advancing additional differentiated compounds from its PRMT5 program. The company secured $60 million in Series B financing (bringing total investments to date to $95 million) to advance PRT543 through proof-of-concept clinical studies and to strengthen discovery, preclinical and clinical development infrastructure. Several early-stage discovery programs have been established and compounds from those programs are expected to enter preclinical development in the second half of 2019, with a potential IND filing in 2020. Management additions announced around the financing include founder and CEO Kris Vaddi, new CMO David Mauro and incoming CFO Brian Piper to support the advancing pipeline.

Total raised

$110M

Funding rounds

2

Latest round

Series C

Latest activity

Aug 2020